Hepatobiliary and pancreatic surgical diseases feasible for laparoscopic surgery
Conditions
Interventions
Experimental group:Robotically-assisted laparoscopic surgery system (NT-ES1000) was used to perform minimally invasive abdominal surgery in hepatobiliary and pancreatic surgery
Sponsors
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age 18-75; (2) It meets the relevant indications of laparoscopic robotic pneumoperitoneo-free cholecystectomy, cholecystectomy + choledochotomy T-tube drainage, liver lesion resection, pancreas lesion resection and splenectomy; (3) There are diagnostic certificates and/or pathological reports of imaging examinations of relevant target lesion sites (1 month before the information is acceptable); (4) Be able to understand and comply with the clinical study protocol, voluntarily participate in the clinical study, and the subject or his legal representative sign a written informed consent.
Exclusion criteria
Exclusion criteria: (1) In patients with severe bleeding tendency, activated partial thromboplastin time >1.5 times the upper limit of normal value; (2) Abdominal infection, peritonitis, diaphragmatic hernia, serious systemic infection; (3) pregnant, lactating women or women planning to give birth; (4) severe abnormal liver and kidney function; (5) Patients with serious cardiovascular or circulatory diseases or suspected or confirmed allergies to surgical anesthetics; (6) Participate in other clinical studies within 1 month before signing the informed consent; (7) Patients who have had abdominal surgery within 1 year before signing the informed consent; (8) Patients diagnosed with ascites or suspected ascites by imaging examination; (9) Patients with a history of gastrointestinal surgery or partial hepatectomy; (10) Epilepsy and other serious neurological diseases; (11) Depression, mania and other serious mental illness; (12) Patients with a history of cerebral infarction or cerebral hemorrhage within 1 year before signing the informed consent; (13) Tumor patients who had received neoadjuvant therapy before signing the informed consent; (14) Other reasons that the researcher considers inappropriate to participate in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| surgical unconversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Instrument-assisted operation time;Intraoperative blood loss;Blood transfusion rate;Instrument defect rate;Incidence of postoperative complications;Incidence of adverse events and serious adverse events;Reoperation rate;30-day readmission rate;Instrument performance evaluation;mortality rate;Subject pain score;Length of stay; | — |
Countries
China
Contacts
Public ContactShengYan
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Outcome results
None listed